0001127537FALSE00011275372024-05-172024-05-17


UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): May 17, 2024

PULMONX CORPORATION
(Exact name of Registrant as Specified in Its Charter)

Delaware001-3956277-0424412
(State or Other Jurisdiction(Commission File Number)(IRS Employer
of Incorporation)Identification No.)
700 Chesapeake Drive
Redwood City,CA94063
(Address of Principal Executive Offices)(Zip Code)
(650)364-0400
Registrant's telephone number, including area code

Not Applicable
(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below):

☐    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered
Common Stock, $0.001 par valueLUNGThe Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐



Item 5.07 Submission of Matters to a Vote of Security Holders.

On May 16, 2024, Pulmonx Corporation (the “Company”) held its 2024 Annual Meeting of Stockholders (the “Annual Meeting”). A total of 34,386,725 shares of the Company’s common stock were present or represented by proxy at the Annual Meeting, which represented approximately 88.59% of the Company’s 38,811,830 shares of common stock that were outstanding and entitled to vote at the meeting as of the record date of March 20, 2024. At the Annual Meeting, the stockholders of the Company considered the three proposals outlined below, each of which is described in more detail in the Company’s definitive proxy statement filed with the Securities and Exchange Commission on April 5, 2024 (the “Proxy Statement”).

Proposal 1 – Election of Directors

The stockholders elected each of the two nominees for Class I director to serve until the Company’s 2027 Annual Meeting of Stockholders and until their successor has been elected and qualified. The voting results were as follows:

ForWithheldBroker Non-Votes
Glendon E. French16,898,79613,685,3283,802,601
Tiffany Sullivan16,725,72413,858,3503,802,601

Proposal 2 – Ratification of Appointment of Independent Registered Public Accounting Firm

The stockholders ratified the appointment of BDO USA, P.C. as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2024. The voting results were as follows:

ForAgainstAbstain
34,338,11738,9379,671

There were no broker non-votes with respect to Proposal 2.

Proposal 3 – Non-Binding Advisory Vote to Approve the Company’s Executive Compensation

The stockholders approved, on a non-binding advisory basis, the Company’s executive compensation as disclosed in the Proxy Statement. The voting results were as follows:

ForAgainstAbstainBroker Non-Votes
16,307,20414,268,1988,7223,802,601


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Pulmonx Corporation

Dated: May 17, 2024

By:/s/ David Lehman
David Lehman
General Counsel

v3.24.1.1.u2
Cover Page
May 17, 2024
Cover [Abstract]  
Document Type 8-K
Document Period End Date May 17, 2024
Entity Registrant Name PULMONX CORPORATION
Entity Incorporation, State or Country Code DE
Entity File Number 001-39562
Entity Tax Identification Number 77-0424412
Entity Address, Address Line One 700 Chesapeake Drive
Entity Address, City or Town Redwood City,
Entity Address, State or Province CA
Entity Address, Postal Zip Code 94063
City Area Code 650
Local Phone Number 364-0400
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, $0.001 par value
Trading Symbol LUNG
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
Entity Central Index Key 0001127537
Amendment Flag false
Pulmonx (NASDAQ:LUNG)
Historical Stock Chart
Von Nov 2024 bis Dez 2024 Click Here for more Pulmonx Charts.
Pulmonx (NASDAQ:LUNG)
Historical Stock Chart
Von Dez 2023 bis Dez 2024 Click Here for more Pulmonx Charts.